India Business Makes Gains At Glenmark While Rest Of World Sees Mixed Results
Plus Firm Settles With Pfizer On Generic Axitinib
Glenmark’s domestic business was seen to gradually strengthen its market share during Q2, while its North American division saw a minor decline in growth and a drop in COVID-related sales took its toll.
You may also be interested in...
Hikma and Glenmark have announced the long-awaited launch of the Ryaltris nasal spray on which the two companies have partnered in the US.
Glenmark signals “very challenging” US environment but expects things to stabilize with a string of potential new launches in the wings. The impending debut of Ryaltris, among other products, and a filing for a generic rival to Flovent could add some spark to the US business.
After nearly two difficult years for Nichi-Iko Pharmaceutical, the firm has announced at it will be acquired by a private equity fund and delisted from the Toyko Stock Exchange in 2023 and its CEO will step down from his post.